CTRI/2023/07/055047尚未招募2 期
A Phase 2 randomized study to assess the radioprotective effect of oral chlorophyllin in acute toxicity reduction for Head Neck cancer patients receiving radiation / chemoradiation. - NI
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A.Patients with histologically proven Squamous Cell Carcinoma of the Oropharynx, Nasopharynx, Oral Cavity, Larynx and Hypopharynx planned for curative intent RT (either definitive or post-op).
- •B. Patients who have not received any other cancer directed treatment in the past.
- •C. Patients willing to sign the informed consent form.
排除标准
- •A. Patients who have received NACT before local therapy
- •B. Patients > 70 years of age
- •C. Patients with severe comorbidities ( > 2 ACE 27 score)
- •D. Patients with baseline feeding tube
- •E. Synchronous / Metachronous Primaries
- •F. Non-Squamous Histology
- •G. Patients receiving non-platinum concurrent chemotherapy
- •H. Treated with palliative intent
- •I. Not reliable for follow up
研究者
相似试验
进行中（未招募）
1 期
A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)on operable oesophageal cancer patientsMedDRA version: 19.1Level: LLTClassification code 10030151Term: Oesophageal cancerSystem Organ Class: 100000004864EUCTR2015-001740-11-GBVelindre NHS Trust
进行中（未招募）
不适用
The SCOPE 2 Trial: Study of chemoradiotherapy in oesophageal cancer including PET response and dose escalatioCancerISRCTN97125464Velindre NHS Trust439
招募中
2 期
Phase II non-randomized study on proton radiotherapy of thymic malignanciescancerThymoma10027655NL-OMON51962Swedish Lung Cancer Study Group10
招募中
2 期
preceding RFA to Atezo+Bev for HCC patientshepatocellular carcinomaJPRN-jRCT1041200075Yamashita Tatsuya66
进行中（未招募）
1 期
A study to investigate the effect of addition of metformin to standard treatment in patients with inoperable stage III non-small cell lung cancer.EUCTR2017-004877-15-BEAntwerp University Hospital, Department Thoracic Oncology104